Ignite Creation Date:
2024-05-06 @ 1:42 PM
Last Modification Date:
2024-10-26 @ 1:18 PM
Study NCT ID:
NCT04095390
Status:
UNKNOWN
Last Update Posted:
2019-09-19
First Post:
2019-09-16
Brief Title:
A Phase Ⅱ Trial of Pyrotinib Combination With CDK46 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
Sponsor:
Jinming Yu
Organization:
Shandong Cancer Hospital and Institute
Organization Data
Organization:
Shandong Cancer Hospital and Institute
Class:
OTHER
Study ID:
HR-BLTN-010
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Jinming Yu
Lead Sponsor Class:
OTHER
Responsible Party:
Jinming Yu
Responsible Party Title:
Director of Shandong Cancer Hospital and Institute
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Shandong Cancer Hospital and Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Jiangsu HengRui Medicine Co Ltd | INDUSTRY |